TUNLUCABTAGENE AUTOLEUCEL
UNII PH4BB8SRL8

Substance Identification & Data

This profile provides standardized clinical and technical data for Tunlucabtagene Autoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) PH4BB8SRL8.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

PH4BB8SRL8

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TUNLUCABTAGENE AUTOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203328

National Cancer Institute reference terminology for clinical and research data.

INN ID

13967

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-70

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tunlucabtagene Autoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TUNLUCABTAGENE AUTOLEUCEL

Common Names & Synonyms

BMS-986453 IS AN INVESTIGATIONAL DRUG PRODUCT CONTAINING CRYOPRESERVED CD3+CAR+ T CELLS THAT HAVE BEEN TRANSDUCED WITH A THIRD-GENERATION, REPLICATION-INCOMPETENT, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR TO EXPRESS A DUAL TARGETING BCMA-SPECIFIC AND GPRC5D-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR INTRAVENOUS ADMINISTRATION. THE DUAL TARGETING CAR CONSISTS OF HUMAN ANTI-BCMA AND ANTI-GPRC5D SCFV BINDING DOMAINS, A MODIFIED HUMAN IGG4 HINGE, A CD28 TRANSMEMBRANE ANCHOR, AND THE 4-1BB AND CD3.ZETA. CHAIN SIGNALING DOMAINS

TUNLUCABTAGENE AUTOLEUCEL [INN]

TUNLUCABTAGENE AUTOLEUCEL [USAN]

External Clinical & Regulatory Resources

Previous UNIIPH45D86M91

Next UNIIPH4DTR6UV2